Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taro Pharmaceutical Industries Ltd.

Latest From Taro Pharmaceutical Industries Ltd.

Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

Legal Issues Deals

Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies

Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.

Deal Watch Business Strategies

Sun Set To Get Taro Deal Over The Line, 17 Years After First Trying

More than a decade after a renewed bid to take control of Taro failed, Sun Pharma is set to take full control of the Israeli-based derma specialist, which has seen material growth and much controversy in the US under Sun’s ownership.

US FDA Adds Capacity For Bioequivalence Studies That Could Help Build Trust In Generics

Agency will fund clinical studies to answer complaints of generic inequivalence and resolve scientific controversies over methods used to support approval.

Generic Drugs Drug Approval Standards
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Thallion Pharmaceuticals, Inc.